Biosimilar versions of other targeted biological therapies for rheumatic diseases are also being developed. Since 2007, Dr. Reddy's Laboratories Ltd. (Hyderabad, India) has marketed Reditux, a biosimilar rituximab, for the treatment of non-Hodgkin's lymphoma and, more recently, as Reditux-RA for the treatment of rheumatoid arthritis [10] . Two other manufacturers of generic drugs are developing biosimilars of rituximab for the treatment of rheumatoid arthritis. Teva Pharma ceutical Industries Ltd. (Petach Tikva, Israel) is conduct ing a phase I/II trial comparing the pharmaco kinetics, pharmacodynamics, safety, and preliminary effi cacy of its biosimilar rituximab TL011 with those of MabTh era® in patients with active rheumatoid arthritis (ClinicalTrials.gov identifi er NCT01123070) [11] . Sandoz, the generics division of Novartis (Basel, Switzerland), has also initiated a phase II clinical trial of its biosimilar rituximab GP2013, assessing similar parameters in patients with rheumatoid arthritis (ClinicalTrials.gov identifi er NCT01274182) [12] .Biosimilar versions of other targeted biological therapies for rheumatic diseases have also begun phase I phar macokinetic and pharmaco dynamic comparative clinical studies [13] .
Although no biosimilars have yet been approved for treatment of a rheumatic disease, the prospect of their impending availability raises several concerns for the rheumatologist: (a) Will a biosimilar be as eff ective as the originally licensed biopharmaceutical? (b) Will a bio similar be as safe as the originally licensed biopharma ceutical? (c) If a pharmacist substitutes a biosimilar for a prescribed biopharmaceutical, will the patient be adversely aff ected? (d) Will the availability of biosimilars reduce the high cost of targeted biological therapies for our patients?
Identical follow-on proteins of certain small peptides, for which the amino acid sequences have been determined, have been synthesized. However, most biosimilars are not identical to the original product but exhibit a range of structural similarities. Proteins produced by recombinant DNA technology are highly similar to the original proteins and share the primary amino acid sequence but diff er with respect to glycosylation and other post-translational modifi cations. Other nonrecom binant proteins that are purifi ed from their natural sources are generally similar to the original biopharmaceuticals but, in addition to exhibiting diff erent posttranslational modifi cations, may have slightly diff erent amino acid sequences.
Distinct from biosimilars are 'second-generation' biopharmaceuticals that are structurally diff erent from the originally licensed biopharmaceutical and that are intended to improve performance while preserving the mechanism of action. However, these second-generation biopharma ceuticals are not usually considered to be follow-on protein products. Major changes in the manufacture of approved protein biopharmaceuticals also introduce a degree of uncertainty similar to that raised by biosimilars. However, in these situations, the original manufacturer maintains access to detailed information that pertains to the changes in production and that would not be available to the manufacturer of a biosimilar.
Manufacturing changes are frequently made by the original developers of protein biopharmaceuticals and their partners. Some production changes have resulted in decreased immunogenicity. When interferon β1a was produced by Biogen Idec (Weston, MA, USA) in a new cell line, the resulting product, Avonex, had decreased immunogenicity compared with the interferon β1a that had been produced in the original Chinese hamster ovary cell line by Bioferon Biochemische Substanzen GmbH & Co. (Laupheim, Germany) [2, 14] . On the other hand, other changes in formulation or packaging have resulted in increased immunogenicity with clinical consequences. A change in the formulation of Eprex (recombinant human erythro poietin manufactured by Ortho Biotech, part of Janssen, Toronto, ON, Canada), switching the protein stabilizer from human serum albumin to the detergent polysorbate 80 and introducing a new packaging system for sub cutaneous administration using a prefi lled syringe with a rubber plunger, resulted in the formation of anti-erythro poietin antibodies that crossreacted with endogenous erythropoietin [15, 16] . Th ese cross-reactive antibodies caused 175 patients receiving this new formulation of Eprex to develop pure red cell aplasia between 1998 and 2004 [17] . Th us, a change in the manufacture of a bio pharmaceutical may result in an outcome that is either benefi cial or detrimental.
In the US, the process whereby protein and peptide drugs, such as enzymes and hormones, are approved and licensed by the US Food and Drug Administration (FDA) is governed by Section 505 of the Food, Drug, and Cosmetic (FD&C) Act (21 US Code [USC] § 355) [18] . In contrast, the process by which large, complex biopharmaceuticals, including the targeted biological agents used to treat rheumatic diseases, are approved and licensed is specifi ed in Section 351 of the PHS Act (42 USC § 262) [1] . Each of these federal statutes mandates that the pharmaceutical manufacturer consult with the FDA, which acts as the representative of the secretary of the US Department of Health and Human Services (HHS), prior to commencing the clinical develop ment program to decide upon the 'design and size of clinical trials of a new drug' that will be necessary for the drug to gain approval [18] .
Th e present system of generic drugs in the US was established by the Drug Price Competition and Patent Term Restoration Act of 1984 (also known as the HatchWaxman Act) (Public Law 98-417). Th is Act amended the FD&C Act and provided two abbreviated pathways for the approval of generic drugs, including natural source products and recombinant proteins [18] . Section 505(b)(2) eliminates the unnecessary duplication of preclinical and some human studies in the New Drug Application (NDA) for a generic drug by allowing direct comparison of the generic drug with a product already approved for the same indication in brief clinical trials of 3 to 6 months in duration. Section 505(j) sets forth the process by which the producer of a generic drug that is identical to a previously approved product can fi le an Abbreviated New Drug Application (ANDA) to seek FDA approval of the generic compound. An ANDA allows the applicant to rely on the FDA's previous fi nding of safety and effi cacy for the already approved drug.
As specifi ed in Section 505(b)(2) of the FD&C Act, the current FDA process for evaluating biosimilar protein and peptide drugs in a marketing application allows the follow-on applicant to rely, in part, on available knowledge about the safety and eff ectiveness of the structurally similar, already approved product. Public access to information about the manufacture of the original product, such as the source material used and any chemical modifi cations that may have been introduced, facilitates this assess ment. However, this evaluation still requires both preclinical and clinical studies to determine the safety, purity, and potency of the biosimilar. In this way, several natural source products and recombinant proteins -for example, natural bovine testicular and recombinant human hyaluronidase, recombinant salmon calcitonin, recombinant human glucagon, and recom binant human somatropin -have been approved as generic drugs under Section 505(b)(2) of the FD&C Act. Th e approval of each relied upon structural characterization, comparative phar ma cokinetic and pharmacodynamic data, and immuno genicity and safety data [2] .
Because of the complexity of large biopharmaceuticals, the manufacturer of a follow-on protein product has diffi culty in demonstrating that it is identical to an already approved product. Th us, the abbreviated approval pathway specifi ed in Section 505(j) of the FD&C Act is not usually available for protein products.
An abbreviated pathway for the approval of biosimilars in the European Union has been proposed by the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). In 2005, guidance was issued outlining the data necessary 'to substantiate the claim of similarity used as the basis for a marketing authorization application (MAA)' for large biopharmaceuticals [19] . Shortly thereafter, the EMA published a guideline that proposed the assessment expected before consideration of an MAA for 'similar biological medicinal products containing biotechnology-derived proteins as active substance' [20] . Both preclinical in vitro assays and in vivo animal studies and clinical studies in patients are required to compare the biosimilar with the reference product. If available, single-and multiple-dose pharmaco kinetic studies and pharmacodynamic studies using biomarkers relevant to the clinical effi cacy of the drug are necessary 'to demonstrate clinical comparability' between the biosimilar and the reference product. In most cases, 'comparative clinical trials' are also needed to demonstrate clinical equivalence between the biosimilar and the already approved reference product and to assess potential immunogenicity with chronic dosing. Because subtle diff erences between the biosimilar and the reference product may result in an unanticipated loss of effi cacy or adverse reactions, careful post-approval pharma co vigilance monitoring is expected. Th e Biosimilar Medicinal Products Working Party of the EMA is in the process of revising these guidelines and preparing other guidelines regarding the assessment of individual biosimilar protein drugs [21] .
In the US, an abbreviated approval pathway for 'highly similar' biological products; the abbreviated BLA permits a follow-on biological product to be evaluated against only a single reference biological product [22] . To be considered for an abbreviated BLA, the biosimilar must have the same presumed mechanism of action, route of administration, dosage form, and potency as the innovator product. It may only be reviewed and approved for indications for which the FDA already has approved the innovator product.
Data obtained from analytical and animal studies and from at least one clinical trial, which must be conducted in patients with a disease for which the innovator product is licensed, are to be used to demonstrate that a follow-on biological product is 'highly similar' to the reference product, 'notwithstanding minor diff erences in clinically inactive components' . Th e clinical study must demonstrate 'safety, purity, and potency' of the follow-on biological product, evaluate its pharmacokinetics and pharma co dynamics, and include an assessment to establish that it is not more immunogenic than the innovator reference product [22] . Once these studies have been completed, the HHS secretary must license an abbreviated BLA if she determines that the information submitted is suffi cient to show that the follow-on biological is 'biosimilar' to or 'interchangeable' with the innovator product [22] . Prior to licensing, the applicant must also consent to inspection of the manufacturing facility to ensure that it follows 'good manufacturing practice' . However, at her 'discretion' , the HHS secretary may 'waive any of these requirements on a case-by-case basis' . Regardless, the same risk evaluation and mitigation strategies (REMSs) required of the innovator biologic agent licensed under the PHS Act are applied to the biosimilar [22] .
Th e FDA has established the Biosimilar Implementation Committee -co-chaired by Janet Woodcock, director of the Center for Drug Research and Evaluation, and Karen Midthun, acting director of the Center for Biologics Evaluation and Research -to determine the process by which the FDA will approach the evaluation, review, and approval of abbreviated BLAs, as mandated by the Biologics Price Competition and Innovation Act [23] . It remains to be specifi ed whether the clinical trials required for an abbreviated BLA may demonstrate noninferiority of the biosimilar to the reference product or must prove superiority of the biosimilar to placebo or to another active comparator. Acceptable measures of effi cacy and the suitability of biomarkers as surrogates for clinical endpoints also remain to be clarifi ed.
A follow-on biological product is defi ned as being 'interchangeable' with the innovator product if it is 'biosimilar' to that product and can be 'expected to produce the same clinical result' as that product in 'any given patient' and if there is no greater risk of safety or diminished effi cacy when alternating or switching between the follow-on biological and innovator products than when using the innovator product with no switch. If these conditions for interchangeability are met, the HHS secretary is required to determine that the biosimilar is 'interchangeable' with the reference product at the time of approval [22] . If so, that biosimilar may be substituted for the prescribed innovator product by someone other than the health-care provider who issued the original prescription. In such a situation, a pharmacist would be allowed to substitute the 'interchangeable' biosimilar for a prescribed targeted biological therapy without involving the patient's rheumatologist. However, unlike small-molecule drugs, a biopharmaceutical that is repeatedly interchanged with a similar biological agent may exhibit immunogenicity that could compromise the effi cacy and safety of both medications. Th e clinical consequences of neutralizing antibodies developing to a non-redundant protein with an important biological function, such as erythropoietin, may be severe [15] . Th us, it is extremely important that there not be frequent switching between the original protein product and the biosimilar, because even subtle diff erences, such as impurities introduced during manufacturing, may trigger an immune response to the biosimilar.
Th e Biologics Price Competition and Innovation Act provides the manufacturer of the innovator product with economic protection by granting a period of 'exclusivity' during which follow-on products may not be approved [22] . A BLA for approval of a follow-on biological product may not be submitted for 4 years after the reference product was initially approved. Th e FDA may not approve a BLA for a follow-on biological product until 12 years after the reference product was fi rst licensed. No additional period of exclusivity will be granted to a previously licensed biologic product when subsequent applications are made for a new indication, route of administration, dosage form, or dosing strength. However, each of the periods of exclusivity may be extended by 6 months if studies of the innovator biological product in the pediatric population are requested by the HHS secretary and carried out.
To encourage the development of biosimilars, the Biologics Price Competition and Innovation Act grants 1 year of exclusive marketing rights to the fi rst follow-on biological that is approved as being 'interchangeable' with a reference product [22] . If patent litigation between the manufacturers of the follow-on and innovator products is ongoing, this period of exclusivity may be extended for up to 42 months.
Th e recently enacted Biologics Price Competition and Innovation Act establishes an abbreviated pathway whereby biosimilars can be evaluated and approved in an accelerated manner. However, the details of the process by which the FDA will implement this pathway have yet to be worked out. As several biosimilar versions of targeted biological therapies for treatment of rheumatoid arthritis are being developed in Asia and Europe, the abbreviated BLA established by this Act sets up a regulatory mechanism for their approval in the US.
Th e Biologics Price Competition and Innovation Act mandates that, to be approved, biosimilars be as safe and eff ective as the originally licensed biopharmaceutical. Although it would be ideal to reduce the cost of development of biosimilars by abbreviating the BLA pathway and to pass that cost savings on to the patient, it is yet to be shown that fewer clinical trials than were required of the innovator biopharmaceutical will provide adequate data regarding the safety and effi cacy of a biosimilar. Meeting conditions of 'interchangeability' will ensure that the patient should not be adversely aff ected if a pharmacist substitutes a biosimilar for a prescribed biopharmaceutical. However, it is not readily apparent that many biosimilars will be determined to be 'interchangeable' with the reference product. Only time and experience will validate the adequacy of this new regulatory pathway for approval of biosimilars in the US.
